Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences Stock Performance
Shares of NASDAQ:PLSE traded up $0.17 during mid-day trading on Tuesday, reaching $1.76. 94,857 shares of the company traded hands, compared to its average volume of 86,751. The company's fifty day moving average is $1.87 and its two-hundred day moving average is $3.85. Pulse Biosciences has a fifty-two week low of $1.41 and a fifty-two week high of $29.16.
Pulse Biosciences (NASDAQ:PLSE - Get Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $0.70 million. As a group, equities research analysts expect that Pulse Biosciences will post -1.66 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. HC Wainwright lowered Pulse Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, May 13th. StockNews.com upgraded Pulse Biosciences to a "sell" rating in a report on Thursday, August 4th. Finally, Stephens downgraded Pulse Biosciences from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 12th.